| Authors: |
Kelly PH; U.S. Medical Affairs, Vaccines, U.S. Commercial Division, Pfizer, Collegeville, PA, USA., Marick HM; Tiber Solutions, VA, USA., Davis J; Global Vaccines Medical Affairs, Pfizer Research & Development, Boston, MA, USA., Takano A; Department of Veterinary Epidemiology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan., Yoshii K; National Research Center for the Control and Prevention of Infectious Diseases (CCPID), Nagasaki University, Nagasaki, Japan., Kawabata H; National Institute of Infectious Diseases (NIID), Tokyo, Japan., Itokawa K; National Institute of Infectious Diseases (NIID), Tokyo, Japan., Sato K; National Institute of Infectious Diseases (NIID), Tokyo, Japan., Lau ACC; Department of Veterinary Epidemiology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.; National Institute of Infectious Diseases (NIID), Tokyo, Japan., Qiu Y; National Institute of Infectious Diseases (NIID), Tokyo, Japan., Pilz A; Global Vaccines Medical Affairs, Pfizer Research & Development, Pfizer, Vienna, Austria., Estrada-Peña A; Senior External Consultant, Ministry of Health, Government of Spain, Madrid, Spain., Angulo FJ; U.S. Medical Affairs, Vaccines, U.S. Commercial Division, Pfizer, Collegeville, PA, USA., Ito S; Vaccines Medical Affairs, Pfizer Japan, Tokyo, Japan., Moïsi JC; Global Vaccines Medical Affairs, Pfizer Research & Development, Paris, France., Nakayama Y; Vaccines Medical Affairs, Pfizer Japan, Tokyo, Japan. |